Antheia, Inc.
Antheia is dedicated to transforming pharmaceutical supply chains by leveraging synthetic biology to produce essential medicines more efficiently, sustainably, and reliably. Their platform enables resilient, scalable, and domestic manufacturing of Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), aiming to address global drug shortages and improve access to critical medicines. With a focus on innovation, sustainability, speed, and reliability, Antheia is pioneering a new standard in pharma manufacturing to meet the demands of 21st-century healthcare.
Industries
Nr. of Employees
small (1-50)
Antheia, Inc.
1430 O’Brien Drive, Suite A, Menlo Park, CA 94025
Patents
Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
US-12180525-B2
View DetailsAntibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies
US-11939379-B2
View Details
Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
US-12180525-B2
View DetailsAntibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies
US-11939379-B2
View DetailsProducts
Microbially produced thebaine
Fermentation-derived thebaine supplied as a biosynthetic precursor for downstream pharmaceutical manufacture.
Microbially produced oripavine
Fermentation-derived oripavine provided as an intermediate in biosynthetic pharmaceutical ingredient pipelines.
Microbially produced scopolamine
Fermentation-derived scopolamine offered as a biosynthetic route to a medicinal alkaloid.
Pipeline of biosynthetic KSMs and APIs
A portfolio comprising multiple key starting materials and active pharmaceutical ingredients at various stages from R&D through commercial production across therapeutic areas.
Microbially produced thebaine
Fermentation-derived thebaine supplied as a biosynthetic precursor for downstream pharmaceutical manufacture.
Microbially produced oripavine
Fermentation-derived oripavine provided as an intermediate in biosynthetic pharmaceutical ingredient pipelines.
Microbially produced scopolamine
Fermentation-derived scopolamine offered as a biosynthetic route to a medicinal alkaloid.
Pipeline of biosynthetic KSMs and APIs
A portfolio comprising multiple key starting materials and active pharmaceutical ingredients at various stages from R&D through commercial production across therapeutic areas.
Services
On-site and partnered fermentation-based production and supply of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs) at pilot and commercial scale.
Assistance with qualification, validation activities, and preparation of regulatory submissions to support customer transition of biosynthetic APIs to market.
End-to-end supply chain design, supplier selection, and procurement practices tailored to onshore and resilient production of KSMs and APIs.
Coordination and management of third-party fermentation CDMO capacity to achieve commercial production targets and support onshoring strategies.
Design and development services for engineered production strains, including genomics-guided enzyme selection, high-throughput screening, and DBTL-supported optimization.
On-site and partnered fermentation-based production and supply of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs) at pilot and commercial scale.
Assistance with qualification, validation activities, and preparation of regulatory submissions to support customer transition of biosynthetic APIs to market.
End-to-end supply chain design, supplier selection, and procurement practices tailored to onshore and resilient production of KSMs and APIs.
Coordination and management of third-party fermentation CDMO capacity to achieve commercial production targets and support onshoring strategies.
Design and development services for engineered production strains, including genomics-guided enzyme selection, high-throughput screening, and DBTL-supported optimization.
Expertise Areas
- Synthetic biology and strain engineering
- Design-Build-Test-Learn (DBTL) workflows
- Biomanufacturing scale-up (fermentation to industrial volumes)
- Fermentation process development and downstream purification
Key Technologies
- Yeast whole-cell engineering
- Next-generation sequencing (NGS) and DNA synthesis
- CRISPR and targeted genome editing
- Laboratory automation and liquid-handling robotics
News & Updates
Christina Smolke, CEO of Antheia, was named to Forbes’ list of top ten women founders in synthetic biology.
Antheia has raised $73 million to advance its mission of producing medicines via synthetic biology.
Highlighting Antheia's potential to address nationwide medicine shortages through advanced biotech.
Antheia announced its first commercial-scale fermentation run producing 116,000 liters of thebaine, a key ingredient for opioids.
Antheia is leveraging synthetic biology to produce medicines currently sourced from plants, with significant funding support.
Insights from Antheia's CEO on navigating the biotech industry during challenging times.
Christina Smolke, CEO of Antheia, was named to Forbes’ list of top ten women founders in synthetic biology.
Antheia has raised $73 million to advance its mission of producing medicines via synthetic biology.
Highlighting Antheia's potential to address nationwide medicine shortages through advanced biotech.
Antheia announced its first commercial-scale fermentation run producing 116,000 liters of thebaine, a key ingredient for opioids.
Antheia is leveraging synthetic biology to produce medicines currently sourced from plants, with significant funding support.
Insights from Antheia's CEO on navigating the biotech industry during challenging times.